MX374758B - Inhibidores de tirosina cinasa de bruton. - Google Patents
Inhibidores de tirosina cinasa de bruton.Info
- Publication number
- MX374758B MX374758B MX2016006744A MX2016006744A MX374758B MX 374758 B MX374758 B MX 374758B MX 2016006744 A MX2016006744 A MX 2016006744A MX 2016006744 A MX2016006744 A MX 2016006744A MX 374758 B MX374758 B MX 374758B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- btk
- bruton
- tyrosine kinase
- kinase inhibitors
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000003844 B-cell-activation Effects 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915582P | 2013-12-13 | 2013-12-13 | |
| PCT/EP2014/077124 WO2015086642A1 (en) | 2013-12-13 | 2014-12-10 | Inhibitors of bruton's tyrosine kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016006744A MX2016006744A (es) | 2016-09-08 |
| MX374758B true MX374758B (es) | 2025-03-06 |
Family
ID=52016584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006744A MX374758B (es) | 2013-12-13 | 2014-12-10 | Inhibidores de tirosina cinasa de bruton. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9556150B2 (enExample) |
| EP (1) | EP3080099B1 (enExample) |
| JP (1) | JP6219523B2 (enExample) |
| KR (1) | KR101768402B1 (enExample) |
| CN (1) | CN105793252B (enExample) |
| CA (1) | CA2931189C (enExample) |
| MX (1) | MX374758B (enExample) |
| RU (1) | RU2648236C2 (enExample) |
| TW (1) | TW201534600A (enExample) |
| WO (1) | WO2015086642A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3080097B1 (en) | 2013-12-13 | 2018-04-18 | F.Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| ES2756175T3 (es) | 2013-12-27 | 2020-04-27 | Chugai Pharmaceutical Co Ltd | Genes mutantes guardián de fgfr y fármacos que se dirigen a los mismos |
| JP6762300B2 (ja) | 2015-06-17 | 2020-09-30 | 中外製薬株式会社 | アミノピラゾール誘導体 |
| WO2017002095A1 (en) | 2015-07-02 | 2017-01-05 | Acerta Pharma B.V. | Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide |
| US10871459B2 (en) | 2017-02-17 | 2020-12-22 | The Regents Of The University Of California | Systems and methods for making assignments in isotope-labelled proteins using nuclear magnetic resonance data |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2025175249A1 (en) | 2024-02-14 | 2025-08-21 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5527819A (en) | 1991-09-06 | 1996-06-18 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
| FR2772763B1 (fr) | 1997-12-24 | 2004-01-23 | Sod Conseils Rech Applic | Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant |
| US6316466B1 (en) * | 1998-05-05 | 2001-11-13 | Syntex (U.S.A.) Llc | Pyrazole derivatives P-38 MAP kinase inhibitors |
| US20030236288A1 (en) | 2002-02-28 | 2003-12-25 | Karl Schoenafinger | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase |
| UA79804C2 (en) | 2002-07-03 | 2007-07-25 | Janssen Pharmaceutica Nv | Cck-1 receptor modulators |
| EP2385037A1 (en) | 2003-06-24 | 2011-11-09 | Chemtura Corporation | Fungicidal phenoxyphenylhydrazine derivatives |
| AU2005225524B2 (en) | 2004-03-26 | 2007-11-22 | F. Hoffmann-La Roche Ag | Tetrahydrocarbazoles and derivatives |
| AU2005323794B2 (en) | 2005-01-07 | 2012-07-19 | Pfizer Products Inc. | Heteroaromatic quinoline compounds and their use as PDE10 inhibitors |
| EP2308839B1 (en) | 2005-04-20 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| FR2892416B1 (fr) | 2005-10-20 | 2008-06-27 | Sanofi Aventis Sa | Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique |
| WO2007056155A1 (en) | 2005-11-03 | 2007-05-18 | Chembridge Research Laboratories, Inc. | Heterocyclic compounds as tyrosine kinase modulators |
| EP1948187A4 (en) | 2005-11-18 | 2010-11-03 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS |
| US8115005B2 (en) | 2006-08-04 | 2012-02-14 | Decode Genetics Ehf. | Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation |
| HRP20150642T1 (hr) | 2006-12-22 | 2015-08-14 | Astex Therapeutics Limited | BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a |
| JP2010523529A (ja) | 2007-04-06 | 2010-07-15 | ノバルティス アーゲー | プロテインキナーゼ調節剤としての２，６−ナフチリジン誘導体 |
| NZ581259A (en) | 2007-05-09 | 2012-07-27 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| US8026257B2 (en) | 2007-07-11 | 2011-09-27 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in CNS disorders |
| TW200920369A (en) | 2007-10-26 | 2009-05-16 | Amira Pharmaceuticals Inc | 5-lipoxygenase activating protein (flap) inhibitor |
| CA2728016C (en) * | 2008-06-24 | 2017-02-28 | F. Hoffmann-La Roche Ag | Novel substituted pyridin-2-ones and pyridazin-3-ones |
| TWI464160B (zh) * | 2009-08-07 | 2014-12-11 | Chugai Pharmaceutical Co Ltd | Amino pyrazole derivative |
| WO2012078859A2 (en) | 2010-12-09 | 2012-06-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Protein kinase d inhibitors |
| JP5620417B2 (ja) | 2011-02-07 | 2014-11-05 | 中外製薬株式会社 | アミノピラゾール誘導体を含む医薬 |
-
2014
- 2014-12-10 MX MX2016006744A patent/MX374758B/es active IP Right Grant
- 2014-12-10 CN CN201480066841.0A patent/CN105793252B/zh not_active Expired - Fee Related
- 2014-12-10 EP EP14809645.6A patent/EP3080099B1/en active Active
- 2014-12-10 US US15/102,832 patent/US9556150B2/en not_active Expired - Fee Related
- 2014-12-10 CA CA2931189A patent/CA2931189C/en active Active
- 2014-12-10 RU RU2016126176A patent/RU2648236C2/ru active
- 2014-12-10 KR KR1020167018757A patent/KR101768402B1/ko not_active Expired - Fee Related
- 2014-12-10 JP JP2016539166A patent/JP6219523B2/ja not_active Expired - Fee Related
- 2014-12-10 WO PCT/EP2014/077124 patent/WO2015086642A1/en not_active Ceased
- 2014-12-11 TW TW103143358A patent/TW201534600A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160097353A (ko) | 2016-08-17 |
| CN105793252A (zh) | 2016-07-20 |
| EP3080099A1 (en) | 2016-10-19 |
| TW201534600A (zh) | 2015-09-16 |
| JP2016540022A (ja) | 2016-12-22 |
| CA2931189A1 (en) | 2015-06-18 |
| US9556150B2 (en) | 2017-01-31 |
| EP3080099B1 (en) | 2018-04-11 |
| KR101768402B1 (ko) | 2017-08-14 |
| US20160311801A1 (en) | 2016-10-27 |
| CN105793252B (zh) | 2018-01-30 |
| RU2648236C2 (ru) | 2018-03-23 |
| WO2015086642A1 (en) | 2015-06-18 |
| MX2016006744A (es) | 2016-09-08 |
| JP6219523B2 (ja) | 2017-10-25 |
| CA2931189C (en) | 2017-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019006622A2 (es) | Derivados de pirazol como inhibidores de malt1 | |
| MX2023000410A (es) | Analogos de rapamicina como inhibidores de mtor. | |
| MX380907B (es) | Compuestos útiles como inhibidores de cinasa. | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| PH12013502379A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| PH12014500128A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| MX374758B (es) | Inhibidores de tirosina cinasa de bruton. | |
| BR112015032595A8 (pt) | inibidores de ido | |
| EA201691514A1 (ru) | Соединения | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| MX2015005015A (es) | Inhibidores heteroarilo de pde4. | |
| GEP20166474B (en) | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors | |
| GEP20166554B (en) | Nitrogenated heterocyclic compound | |
| JO3466B1 (ar) | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 | |
| WO2014064131A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| PH12015502737A1 (en) | Novel fused pyrimidine compound or salt thereof | |
| MX2015010466A (es) | Inhibidores de tirosina cinasa de bruton. | |
| MX2016006763A (es) | Inhibidores de tirosina cinasa de bruton. | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| EA201790207A1 (ru) | Новые замещенные пиримидиновые соединения | |
| MX2015010983A (es) | Inhibidores de tirosina-cinasa de bruton. | |
| MX374759B (es) | Inhibidores de tirosina cinasa de bruton. | |
| EA201590379A1 (ru) | Пирролопиразолы, используемые в качестве блокаторов кальциевых каналов n-типа | |
| MX2015013936A (es) | Compuestos de pirimidina condensada sustituida. | |
| MX2015007291A (es) | Derivados de tiazol como inhibidores de la tirosina cinasa de bruton. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |